English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.49 |
| Open | 0.48 |
| 1-Year Change | -55.56% |
| Day's Range | 0.48 - 0.49 |
Orgenesis Inc. is a biotech company operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous (using the patient’s own cells) therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment. The Company has developed a Point of Care Platform comprised of three components: POCare Therapies, POCare Technologies and POCare Network. Its therapeutic portfolio pipeline is diverse and addresses various clinical needs. POCare Technology uses automated systems across a collaborative POCare Network via a combination of science, technology, engineering and networking.
BRIEF: For the nine months ended 30 September 2021, Orgenesis Inc revenues increased from $5.4M to $28.6M. Net loss before extraordinary items decreased 70% to $13M. Revenues reflect POC Services segment increase from $4.3M to $17.1M, Cell process development services segment increase from $1.1M to $11.5M. Lower net loss reflects Other research and development expenses decrease of 43% to $5.6M (expense).
Common Stock $.001 Par, 4/13, 1.75B auth., 49,617,903 issd. Insider owns approx.50.56% Effective August 31, 2011 effected a 35 to one forward stock split
